Sorafenib (SOR) plus chemotherapy (CRx) in patients (pts) with triple-negative (TN) advanced (adv) breast cancer (BC): Subgroup analyses of 3, double-blind, randomised, placebo (PL)-controlled phase 2b trials from the TIES (Trials to Investigate the Efficacy of Sorafenib) BC program Meeting Abstract
| Authors: | Hudis, C. A.; Baselga, J.; Gradishar, W. J.; Tauer, K. W.; Hermann, R. C.; Gomez, P.; Roche, H.; Kaklamani, V.; Sahoo, T. P.; Schwartzberg, L. |
| Abstract Title: | Sorafenib (SOR) plus chemotherapy (CRx) in patients (pts) with triple-negative (TN) advanced (adv) breast cancer (BC): Subgroup analyses of 3, double-blind, randomised, placebo (PL)-controlled phase 2b trials from the TIES (Trials to Investigate the Efficacy of Sorafenib) BC program |
| Meeting Title: | IMPAKT 2011 Breast Cancer Conference |
| Journal Title: | Annals of Oncology |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2011 May 5-7 |
| Meeting Location: | Brussels, Belgium |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2011-05-01 |
| Start Page: | ii54 |
| Language: | English |
| ACCESSION: | WOS:000290610100109 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdr089 |
| PUBMED: | 21568012 |
| Notes: | Meeting Abstract: 117P -- "Source: Wos" |
